Being on the track of thimerosal review

Acta Microbiologica et Immunologica Hungarica

Volumn 52, Issue 1, 2005, Pages 95-103

  Madi A ^a  

^a UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Autism; Neurodevelopmental disorder; Programmed cell death; Vaccine

Indexed keywords

CONTACT ALLERGEN; DIPHTHERIA VACCINE; HEPATITIS B VACCINE; ORGANOMERCURY COMPOUND; PERTUSSIS VACCINE; PRESERVATIVE; TETANUS TOXOID; THIOMERSAL; VACCINE;

ALZHEIMER DISEASE; APOPTOSIS; AUTISM; CAENORHABDITIS ELEGANS; CELL DEATH; CELL FUNCTION; CONTACT ALLERGY; DEVELOPMENTAL DISORDER; HUMAN; HUNTINGTON CHOREA; NERVE CELL DIFFERENTIATION; REVIEW;

EID: 18844375042     PISSN: 12178950     EISSN: None     Source Type: Journal    
DOI: 10.1556/AMicr.52.2005.1.5     Document Type: Review

References (53)

1. Magos, L.: Neurotoxic character of thimerosal and the allometric extrapolation of adult clearance half time to infants. J Appl Toxicol 23, 263-269 (2003).
2. Risher, J. F., Murray, H. E., Prince, G. R.: Organic mercury compounds: human exposure and its relevance to public health. Toxicol Ind Health 18, 109-160 (2002).
3. Clarkson, T. W.: The three modern faces of mercury. Environ Health Perspect 110, 11-23 (2002).
4. Audicuna, M. T., Munoz, D., Dolores del Pozo, M. et al.: Thimerosal sensitivity in patch tests is usually irrelevant. The reason for this may be the presence of thimerosal in childhood vaccinations. Am J Contact Dermatitis 13, 3-9 (2002).
5. Alexandre, H., Delsine, V., Goval, J. J., Van Cauwenberge, A.: Effect of taxol and okadaic acid on microtubule dynamics in thimerosal-arrested primary mouse oocytes: a confocal study. Biol Cell 95, 407-414 (2003).
6. Alexandre, H., Delsinne, V., Goval, J. J.: The thiol reagent, thimerosal, irreversibly inhibits meiosis reinitiation in mouse oocyte when applied during a very early and narrow temporal window: a pharmacological analysis. Mol Reprod Dev 65, 454-461 (2003).
7. Muller, M., Westphal, G., Vesper, A., Bunger, J., Hallier, E.: Inhibition of the human erythrocytic glutathione-S-transferase T1 (GST T1) by thimerosal. Int J Hyg Environ Health 203, 479-481 (2001).
8. Kiffe, M., Christen, P., Arni, P.: Characterization of cytotoxic and genotoxic effects of different compounds in CHO K5 cells with the comet assay (single cell gel electrophoresis assay). Mutat Res 537, 151-168 (2003).
9. Baskin, D. S., Ngo, H., Didenki, V. V.: Thimerosal induces DNA breaks, caspase-3 activation, membrane damage, and cell death in cultured human neurons and fibroblasts. Toxicol Sci 74, 361-368 (2003).
10. Jan, C. R., Jiann, B. P., Lu, Y. C., Chang, H. T., Yu, C. C., Chen, W. C., Huang, J. K.: Oxidation by thimerosal increases calcium levels in renal tubular cells. Pharmacol Toxicol 93, 123-127 (2003).
11. 2+ mobilization in isolated guinea pig cochlear outer hair cells. Zhonghua Er. Bi. Yan. Hou Ke Za Zhi 35, 192-195 (2000).
12. 2+ release in intact HeLa cells seen with aequorin targeted to the endoplasmatic reticulum. Cell Calcium 30, 181-190 (2001).
13. 2+ oscillations in the HSY salivary duct cell line. Biochim Biophys Acta 1539, 114-121 (2001).
14. 2+ release activities in bovine adrenal cortex microsomes. Endocrinology 142, 2614-2621 (2001).
15. Vanlingen, S., Sipma, H., De Smet, P., Callewaert, G., Missiaen, L., De Smedt, H., Parys, J. B.: Modulation of inositol 1,4,5-triphosphate binding to the various inositol 1,4,5-trisphosphate receptor isoforms by thimerosal and cyclic ADP-ribose. Biochem Pharmacol 61, 803-809 (2001).
16. Elferink, J. G.: Thimerosal: a versatile sulfhydryl reagent, calcium mobilizer, and cell function-modulating agent. Gen Pharmacol 33, 1-6 (1999).
17. Kim, E., Kim, J. H., Kim, H. S., Ryu, S. H., Suh, P. G.: Thimerosal stimulates focal adhesion kinase and cytoskeletal changes by redox modulation. Biochim Biophys Acta 1593, 9-15 (2002).
18. Makani, S., Gollapudi, S., Yel, L., Chiplunkar, S., Gupta, S.: Biochemical and molecular basis of thimerosal-induced apoptosis in T cells: a major role of mitochondrial pathway. Genes Immun 3, 270-278 (2002).
19. Qvarnstrom, J., Lambertsson, L., Havarinasab, S., Hultman, P., Frech, W.: Determination of methylmercury, ethylmercury, and inorganic mercury in mouse tissues, following administration of thimerosal, by species-specific isotop dilution GC-inductively coupled plasma MS. Anal Chem 75, 4120-4124 (2003).
20. Tan, M., Parkin, J. E.: Route of decomposition of thiomersal (thimerosal). Int J Pharm 208, 23-34 (2000).
21. Westphal, G. A., Schnuch, A., Schulz, T. G., Reich, K., Aberer, W., Brasch, J., Koch, P., Wessbecher, R., Szliska, C., Bauer, A., Hallier, E.: Homozygous gene deletions of the glutathione S-transferases M1 and T1 are associated with thimerosal sensitization. Int Arch Occup Environ Health 73, 384-388 (2000).
22. Marks, J. G., Belsito, D. V., Deleo, V. A., Fowler, J. F., Fransway, A. F., Maibach, H. I., Mathias, C. G., Pratt, M. D., Rietschel, R. L., Sherertz, E. F., Storrs, F. J., Taylor, J. S.: The frequency of positive reactions to thimerosal on patch tests in North America. Arch Dermatol 136, 272-273 (2000).
23. Trattner, A., Farchi, Y., David, M.: The frequency of positive reaction to thimerosal on patch test in Israel. Contact Dermatitis 47, 180-181 (2002).
24. Thompson, T. R., Belsito, D. V.: Regional variations in prevalence and etiology of thimerosal sensitivity is non-specific. Am J Contact Dermatitis 13, 177-182 (2002).
25. Suneja, T., Belsito, D. V.: Thimerosal in the detection of clinically relevant allergic contact reactions. J Am Acad Dermatol 45, 23-27 (2001).
26. Wohrl, S., Hemmer, W., Focke, M., Gotz, M., Jarisch, R.: Patch testing in children, adults, and the elderly; influence of age and sex on sensitization patterns. Pediatr Dermatol 20, 119-123 (2003).
27. No authors listed: Thimerosal in vaccines: a joint statement of the American Academy of Pediatrics and the Public Health Service. MMWR Morb Mortal Wkly Rep 48, 563-565 (1999).
28. Frankish, H.: Report finds no link between thimerosal and neurodevelopmental disorders. Lancet 358, 1163 (2001).
29. van't Veen, A. J.: Vaccines without thimerosal: why so necessary, why so long coming? Drugs 61, 565-572 (2001).
30. Geier, M. R., Geier, D. A.: Neurodevelopmental disorders after thimerosal-containing vaccines: a brief communication. Exp Biol Med 3, 660-664 (2003).
31. No authors listed: Update: expanded availability of thimerosal preservative-free hepatitis B vaccine. MMWR Morb Mortal Wkly Rep 49, 642, 651 (2000).
32. Wong, K.: The search for autism's roots. Nature 411, 882-884 (2001).
33. Kidd, P. M.: Autism, an extreme challenge to integrative medicine. Part: 1: The knowledge base. Altern Med Rev 7, 292-316 (2002).
34. Bernard, S., Enayati, A., Redwood, L., Roger, H., Binstock, T.: Autism: a novel form of mercury poisoning. Med Hypotheses 56, 462-471 (2001).
35. Reading, R.: Thimerosal and the occurrence of autism: negative ecological evidence from Danish population-based data. Child Care Health Dev 30, 90-91 (2004).
36. Hviid, A., Stellfeld, M., Wohlfahrt, J., Melbye, M.: Association between thimerosal-containing vaccine and autism. JAMA 290, 1763-1766 (2003).
37. Stehr-Green, P., Tull, P., Stellfeld, M., Mortenson, P. B., Simpson, D.: Autism and thimerosal-containing vaccines: lack of consistent evidence for an association. Am J Prev Med 25, 101-106 (2003).
38. Holmes, A. S., Blaxill, M. F., Haley, B. E.: Reduced levels of mercury in first baby haircuts of autistic children. Int J Toxicol 22, 277-285 (2003).
39. Yuan, J.: Evolutionary conservation of a genetic pathway of programmed cell death. J Cell Bioch 60, 4-11 (1996).
40. Margolis, R. L., Chuang, D. M., Post, R. M.: Programmed cell death: implications for neuropsychiatric disorders. Biol Psychiatry 35, 946-956 (1994).
41. Fatemi, S. H., Stary, J. M., Halt, A. R., Realmuto, G. R.: Dysregulation of Reelin and Bcl-2 proteins in autistic cerebellum. J Autism Dev Disord 31, 529-535 (2001).
42. Fatemi, S. H., Halt, A. R.: Altered levels of Bcl-2 and p53 proteins in parietal cortex reflect deranged apoptotic regulation in autism. Synapse 42, 281-284 (2001).
43. Fatemi, S. H., Halt, A. R., Stary, J. M., Realmuto, G. M., Jalali-Mousavi, M.: Reduction in anti-apoptotic protein Bcl-2 in autistic cerebellum. Neuroreport 12, 929-933 (2001).
44. Aboobaker, A. A., Blaxter, M. L.: Medical significance of Caenorhabditis elegans. Ann Med 32, 23-30 (2000).
45. Ruvkun, G.: Patterning the nervous system. In Riddle, D. L., Blumenthal, T., Meyer, B. J., Priess, J. R. (eds): C. elegans II. Cold Spring Harbor Laboratory Press, Plainview, USA 1997, pp. 543-583.
46. Link, C. D.: Transgenic invertebrate models of age-associated neurodegenerative diseases. Mech Ageing Dev 122, 1639-1649 (2001).
47. Driscoll, M., Gerstbrein, B.: Dying for a cause: invertebrate genetics takes on human neurodegeneration. Nat Rev Genet 4, 181-194 (2003).
48. Williams, P. L., Dusenbery, D. B.: A promising indicator of neurobehavioral toxicity using the nematode Caenorhabditis elegans and computer tracking. Toxicol Ind Health 6, 425-440 (1990).
49. Khanna, N., Cressman, C. P. 3rd, Tatara, C. P., Williams, P. L.: Tolerance of the nematode Caenorhabditis elegans to pH, salinity, and hardness in aquatic media. Arch Environ Contam Toxicol 32, 110-114 (1997).
50. Marroquin, L. D., Elyassnia, D., Griffitts, J. S., Feitelson, J. S., Aroian, R. V.: Bacillus thuringiensis (Bt) toxin susceptibility and isolation of resistance mutants in the nematode Caenorhabditis elegans. Genetics 155, 1693-1699 (2000).
51. Griffitts, J. S., Whitacre, J. L., Stevens, D. E., Aroian, R. V.: Bt toxin resistance from loss of a putative carbohydrate-modifying enzyme. Science 293, 860-864 (2001).
52. Kimmel, S. R.: Vaccine adverse events: separating myth from reality. Am Fam Physician 66, 2113-2120 (2002).
53. No authors listed: Thimerosal as vaccine preservative. Wkly Epidemiol Rec 75, 12-16 (2000).